FRONGEVI Trademark

Trademark Overview

On Thursday, October 11, 2012, a trademark application was filed for FRONGEVI with the United States Patent and Trademark Office. The USPTO has given the FRONGEVI trademark a serial number of 85751723. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 27, 2016. This trademark is owned by Millennium Pharmaceuticals, Inc.. The FRONGEVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use, namely, for the treatment of hematological malignancies, cancer, auto-immune diseases and disorders and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of cancer
frongevi

General Information

Serial Number85751723
Word MarkFRONGEVI
Filing DateThursday, October 11, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 27, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 26, 2013

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use, namely, for the treatment of hematological malignancies, cancer, auto-immune diseases and disorders and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 17, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMillennium Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameMillennium Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, June 27, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, June 27, 2016ABANDONMENT - NO USE STATEMENT FILED
Thursday, November 5, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 4, 2015EXTENSION 5 GRANTED
Monday, October 26, 2015EXTENSION 5 FILED
Monday, October 26, 2015TEAS EXTENSION RECEIVED
Friday, May 15, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 14, 2015EXTENSION 4 GRANTED
Tuesday, April 28, 2015EXTENSION 4 FILED
Tuesday, April 28, 2015TEAS EXTENSION RECEIVED
Thursday, November 13, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 12, 2014EXTENSION 3 GRANTED
Thursday, October 30, 2014EXTENSION 3 FILED
Thursday, October 30, 2014TEAS EXTENSION RECEIVED
Wednesday, May 14, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 13, 2014EXTENSION 2 GRANTED
Monday, April 21, 2014EXTENSION 2 FILED
Wednesday, May 7, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 21, 2014TEAS EXTENSION RECEIVED
Friday, November 1, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2013EXTENSION 1 GRANTED
Wednesday, October 30, 2013EXTENSION 1 FILED
Wednesday, October 30, 2013TEAS EXTENSION RECEIVED
Wednesday, October 30, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 21, 2013NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 26, 2013PUBLISHED FOR OPPOSITION
Wednesday, March 6, 2013NOTICE OF PUBLICATION
Thursday, February 14, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 8, 2013ASSIGNED TO EXAMINER
Wednesday, October 17, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 15, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

frongevi diseases pharmaceutical cancer treatment disorders preparations inflammatory immune malignancies human